[1] ATUL TIWARI Pranab M. TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders.[J]. Drug Discovery Today, 2009, 14 9-10: 523-530. DOI:
10.1016/j.drudis.2009.02.005[2] XIAOXIN X WANG. G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes.[J]. Journal of The American Society of Nephrology, 2016: 1362-1378. DOI:
10.1681/asn.2014121271[3] ANA M P MELO Miguel T Tiago M Bandeiras. New insights into type II NAD(P)H:quinone oxidoreductases.[J]. Microbiology and Molecular Biology Reviews, 2004, 68 4: 603-616. DOI:
10.1128/mmbr.68.4.603-616.2004[4] WEIBIAO CAO. Expression of bile acid receptor TGR5 in gastric adenocarcinoma.[J]. American journal of physiology. Gastrointestinal and liver physiology, 2013, 304 4: G322-7. DOI:
10.1152/ajpgi.00263.2012[5] JIE HONG. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma.[J]. Gut, 2010, 59 2: 170-180. DOI:
10.1136/gut.2009.188375